PRC-4016 + statins

PRC-4016 + statins is an oral combination therapy involving **PRC-4016 (also known as icosabutate)** and one or more **statins** (such as simvastatin). PRC-4016 is a structurally modified fatty acid derivative primarily investigated for its lipid-lowering properties. Statins are a well-established class of HMG-CoA reductase inhibitors used to lower cholesterol levels. This combination is under investigation for synergistic or additive effects in the reduction of plasma lipids, including LDL-cholesterol, with the aim of enhancing efficacy while potentially mitigating dose-dependent statin adverse effects. Typical studies assess pharmacokinetic interactions and the impact of coadministration compared to monotherapy. The combination is being evaluated for the management of dyslipidemias, including mixed dyslipidemia, and the reduction of cardiovascular risk[1][3][4].

Other names

icosabutate + statins